dose-esc/exp rmc4630 & cobi in relapsed/refractory solid tumors & rmc4630& osi in egfr+ locally adv/meta nsclc

Conditions: Solid Tumor

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (pk), and pharmacodynamic (pd) proﬁles of rmc-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific genomic aberrations and to identify the recommended phase 2 dose (rp2d); and to evaluate the safety, tolerability, pharmacokinetic (pk), and pharmacodynamic (pd) proﬁles of rmc-4630 and osimertinib in adult participants with egfr mutation-positive locally advanced or metastatic nsclc.

this open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate the safety and maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d) of rmc-4630 in combination with cobimetinib in participants with relapsed/refractory solid tumors; and of rmc-4630 in combination with osimertinib in adult participants with egfr mutation-positive locally advanced or metastatic nsclc.

Eligibility criteria:
inclusion criteria: * age ≥18 years * for rmc-4630 + cobimetinib only - participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anti-cancer treatments including approved drugs for oncogenic drivers in their tumor type. * for rmc-4630 + osimertinib only - locally advanced or metastatic egfr mutant nsclc not amenable to curative surgery or radiotherapy * for rmc-4630 + cobimetinib only - participants must have one of the following genotypic aberrations: kras mutations and amplifications, braf class 3 mutations, or nf1 lof mutations * for rmc-4630 + osimertinib only - evidence of radiological documentation of progression with osimertinib monotherapy or an osimertinib containing regimen. participants should not be considered a current candidate for 1st generation egfr tki's by the investigator. * eastern cooperative oncology group (ecog) performance status of ≤1 * adequate hematological, hepatic, and renal function * capable of giving signed informed consent form (icf). willing and able to compile with study requirements and restrictions * life expectancy \>12 weeks * female of childbearing potential and males with partners of childbearing potential must comply with effective contraception criteria . exclusion criteria: * primary central nervous system (cns) tumors. * known or suspected leptomeningeal or brain metastases or spinal cord compression. * for rmc-4630 + osimertinib arm only - known or suspected small cell, squamous, or pleomorphic lung transformations * clinically significant cardiac disease * active, clinically signiﬁcant interstitial lung disease or pneumonitis * history or current evidence of retinal pigment epithelial detachment (rped), central serous retinopathy, retinal vein occlusion (rvo), or predisposing factors to rped or rvo * known hiv infection or active/chronic hepatitis b or c infection. * any other unstable or clinically signiﬁcant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy * females who are pregnant or breastfeeding

Keywords: shp2 ptpn11 nsclc kras g12 braf class 3 nf1 lof kras amplification kras mutations advanced solid tumor advanced solid malignancies bladder cancer carcinoma, non-small-cell lung neoplasm, squamous cell carcinoma, squamous cell esophageal neoplasms carcinoma, bronchogenic bronchial neoplasms lung neoplasms respiratory tract neoplasms thoracic neoplasms neoplasms by site neoplasms lung diseases respiratory tract diseases gastrointestinal cancer colorectal cancer skin cancer ovarian cancer pancreatic cancer endometrium/uterus cancer cervical cancer